A small-molecule VHL molecular glue degrader for cysteine dioxygenase 1

  • Nat Chem Biol. 2025 Nov;21(11):1688-1696. doi: 10.1038/s41589-025-01936-x.
Antonin Tutter  1 Dennis Buckley  1 Andrei A Golosov  2 Xiaolei Ma  3 Wei Shu  3 Daniel J J McKay  2 Veronique Darsigny  1 Dustin Dovala  4 Rohan Beckwith  1 Jonathan Solomon  1 Pasupuleti Rao  1 Lei Xu  1 Aleem Fazal  1 Andreas Lingel  5 Charles Wartchow  4 Jennifer S Cobb  1 Amanda Hachey  1 Jennifer Tullai  1 Gregory A Michaud  6
Affiliations
  • 1. Discovery Sciences, Novartis Biomedical Research, Cambridge, MA, USA.
  • 2. Global Discovery Chemistry, Novartis Biomedical Research, Cambridge, MA, USA.
  • 3. Global Discovery Chemistry, Novartis Biomedical Research, Emeryville, CA, USA.
  • 4. Discovery Sciences, Novartis Biomedical Research, Emeryville, CA, USA.
  • 5. Global Discovery Chemistry, Novartis Biomedical Research, Basel, Switzerland.
  • 6. Discovery Sciences, Novartis Biomedical Research, Cambridge, MA, USA. [email protected].
Abstract

The von Hippel-Lindau tumor suppressor gene product (pVHL) is an E3 Ligase substrate receptor that binds proline-hydroxylated hypoxia-inducible factor HIF1α, leading to its ubiquitin-dependent degradation. By using protein arrays, we identified a small molecule that binds the HIF1α-binding pocket on pVHL and functions as a molecular glue degrader of the neosubstrate cysteine dioxygenase (CDO1) by recruiting it into the VHL-Cullin-RING E3 Ligase complex and leading to its selective degradation. The CDO1-binding region involved in VHL recruitment was characterized through a combination of mutagenesis and protein-protein docking coupled with molecular-dynamics-based solvation analysis. The X-ray structure of the ternary complexes of VHL, CDO1 and degrader molecules confirms the binding region prediction and provides atomic insights into key molecular glue interactions.

Products